A weaker start to 2023 shouldn’t be a concern and, given that the full-year guidance has been maintained, Virbac should be able to compensate in the subsequent quarters. Both its segments are well positioned to achieve healthy medium-to-long term growth, which should find impetus from the ongoing R&D investment and Chinese expansion plans. Moreover, Dechra’s (the firm’s peer) potential takeover at a high premium to its undisturbed valuation bodes well for Virbac’s ongoing re-rating.
18 Apr 2023
Q1 miss is no major reason to worry
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1 miss is no major reason to worry
- Published:
18 Apr 2023 -
Author:
Abhishek Raval -
Pages:
3
A weaker start to 2023 shouldn’t be a concern and, given that the full-year guidance has been maintained, Virbac should be able to compensate in the subsequent quarters. Both its segments are well positioned to achieve healthy medium-to-long term growth, which should find impetus from the ongoing R&D investment and Chinese expansion plans. Moreover, Dechra’s (the firm’s peer) potential takeover at a high premium to its undisturbed valuation bodes well for Virbac’s ongoing re-rating.